Best in Biotech 26 Aug 2025 Five biotech companies in South Korea you should know about …with first-in-class therapies and its proteomics platform – the study of proteins – to discover biomarkers. While its pipeline focuses on different kinds of diseases like cancer, infectious diseases, lung,… August 26, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 May 2024 Biotech in New Jersey: Nine companies leading the charge …immunotherapies for cancer and infectious diseases using its proprietary Versamune platform. This platform is designed to enhance the body’s immune response against diseases by activating T cells in a way… May 7, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2017 Evotec launches New Biotech to tackle the Most Deadly Diseases …in the new company, which will develop first-in-class therapeutics for fibrotic diseases. Fibrotic diseases, which include chronic kidney disease, liver fibrosis, systemic sclerosis, pulmonary fibrosis, myocardial infarction, stroke and cancer,… January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2019 Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial A drug, developed by the Danish biotech Orphazyme for a rare metabolic disease, has shown promising results in a phase II/III trial, reducing the disease’s progression by 74%. The 50… January 30, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 16 Dec 2025 Biotech in 2025: A retrospective …like a phase shift, where many trends that had been building finally started to matter in practice. Metabolic medicines, especially GLP-1 and related incretin therapies, continued to dominate both research… December 16, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2025 Swiss biotech going strong in 2025: 19 companies to put on your radar …metabolic disease and other age-related disorders. ImmunOs Therapeutics Founded: 2018 Focus: HLA-based multifunctional immunotherapies Lead candidate: IOS-1002 This Swiss biotech company is focused on developing therapies for cancer and autoimmune diseases. Their approach… November 12, 2025 - 20 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2024 Top biotech deals of November 2024 …earn up to $745 million in upfront and milestone payments. Finally, pharma giant Novo Nordisk continues its streak with the metabolic and heart diseases therapeutic field. It has tapped Ascendis… December 12, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 30 Dec 2020 A Look Back at the Past Decade of European Biotech …this field seek to tackle aging-related diseases. Why is this so important? According to Alexandra Bause, a wide range of diseases can be attributed to aging. “In our 20s, 30s,… December 30, 2020 - 15 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
In Depth 26 Sep 2024 The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond …SPECT to visualize biological processes within the body. These tracers often target specific biomarkers or metabolic pathways associated with diseases, especially cancer. Examples of commercially available radiotracers include fluorodeoxyglucose (FDG),… September 26, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS …a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding… August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 3 Nov 2022 What’s on the horizon for gene editing-based therapies? …adding that future pioneers could “completely upend the way we are doing things.” Picture/Shutterstock From rare diseases to bigger indications One reason that gene editing companies treat rare diseases is… November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases …worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle and heart diseases that cannot… June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email